Study of Macronutrients and Heart Disease Risk (MACRO)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00609271 |
|
Recruitment Status :
Completed
First Posted : February 7, 2008
Results First Posted : November 19, 2018
Last Update Posted : November 19, 2018
|
Sponsor:
Tulane University Health Sciences Center
Information provided by (Responsible Party):
Lydia A. Bazzano, Tulane University Health Sciences Center
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The objective of this trial is to examine the long-term effects of a diet low in carbohydrates, as compared to one low in fat, on cardiovascular disease risk factors, including blood pressure (BP), body weight and composition, serum lipids, plasma glucose, insulin, adipocytokines (adiponectin, leptin, resistin), and C-reactive protein (CRP) among obese adults.
The investigators will test the following hypotheses:
Hypothesis 1: Compared to a low fat diet, a diet low in carbohydrates will reduce systolic and diastolic BP over 12 months; Hypothesis 2: Compared to a low fat diet, a diet low in carbohydrates will reduce body weight, total percent body fat, and waist circumference over 12 months; Hypothesis 3: Compared to a low fat diet, a diet low in carbohydrates will reduce serum levels of LDL-cholesterol and triglycerides and increase serum levels of HDL-cholesterol over 12 months; Hypothesis 4: Compared to a low fat diet, a diet low in carbohydrates will reduce plasma levels of glucose and insulin levels over 12 months; and Hypothesis 5: Compared to a low fat diet, a diet low in carbohydrates will reduce plasma levels of leptin, resistin, and CRP and increase plasma levels of adiponectin over 12 months.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Obesity Body Composition Blood Pressure Cardiovascular Diseases | Behavioral: low carbohydrate diet Behavioral: low fat diet | Not Applicable |
Cardiovascular diseases (CVD) remain the leading cause of death globally as well as here in the United States. Manipulations of the macronutrient (protein, carbohydrate and fat) contents of diet have been used extensively for weight loss and weight control in the past several decades. Low carbohydrate diets, in particular, have gained popularity for weight loss. However, few studies have examined the effects of a diet low in carbohydrates on traditional and novel cardiovascular risk factors in the long term, particularly in contrast to the current dietary recommendations for decreased fat intake to reduce risk of CVD. In this proposal, we plan to conduct a 12-month, parallel-arm, randomized controlled trial of a diet low in carbohydrates versus the currently recommended low fat diet to reduce CVD risk factors among obese adults. The objective of this trial is to examine the long-term effects of a diet low in carbohydrates, as compared to one low in fat, on CVD risk factors, including blood pressure (BP), body weight and composition, serum lipids, plasma glucose, insulin, adipocytokines (adiponectin, leptin, resistin), and C-reactive protein (CRP) among obese adults. In order to accomplish these objectives we will randomize 130 eligible participants (n=65 in each group) to consume either a diet low in carbohydrates (≤40 g/d) or a diet low in fat (<7% saturated fat, <30% total fat). Neither of the diets will be energy-restricted. Participants will meet with a dietitian for one-on-one counseling sessions weekly for the first 4 weeks, then bi-monthly in small group sessions for the next 5 months, and monthly in larger group sessions for the final 6 months of the intervention. Data on both traditional and novel CVD risk factors will be collected at baseline, 3, 6, and 12 months. We hypothesize that a diet low in carbohydrates as compared to a diet low in fat will lower systolic and diastolic BP, body weight, total percent body fat, waist circumference, serum levels of triglycerides, and plasma levels of insulin, glucose, leptin, resistin, and CRP, and increase serum levels of HDL-cholesterol and adiponectin. Because CVD is the most common cause of death here in the U.S. and world-wide, this study has important public health implications. It will provide new information on the potential long-term effects of diets low in carbohydrates on both the traditional risk factors for CVD as well as novel risk factors and inflammatory factors. The results from this study will help to determine if a diet low in carbohydrates as compared to the currently recommended low fat diet can decrease the risk of CVD among obese adults.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 148 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Prevention |
| Official Title: | Macronutrient Composition of Diet and Risk Factors for Cardiovascular Disease |
| Study Start Date : | January 2008 |
| Actual Primary Completion Date : | January 2011 |
| Actual Study Completion Date : | January 2012 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 1
low carbohydrate diet
|
Behavioral: low carbohydrate diet
<40 grams carbohydrate/day |
|
Active Comparator: 2
low fat diet
|
Behavioral: low fat diet
<30% fat, <7% saturated fat |
Primary Outcome Measures :
- Predicted Mean Difference in Body Weight From Baseline, by Assigned Dietary Group [ Time Frame: 12 months ]Predicted mean difference from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences in Lean Mass From Baseline, by Assigned Dietary Group [ Time Frame: 12 months ]Mean Difference in Lean Mass predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences in Fat Mass From Baseline, by Assigned Dietary Group [ Time Frame: 12 months ]Mean Difference in Fat Mass predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences of Waist Circumference From Baseline, by Assigned Dietary Group [ Time Frame: 12 months ]Predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences in Total Cholesterol Level From Baseline by Assigned Dietary Group [ Time Frame: 12 months ]Predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences in LDL Cholesterol Level From Baseline, by Assigned Dietary Group [ Time Frame: 12 months ]Predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences in HDL Cholesterol From Baseline, by Assigned Dietary Group [ Time Frame: 12 months ]Predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences in Total-HDL Cholesterol Ratio From Baseline, by Assigned Dietary Group [ Time Frame: 12 months ]Predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences in Triglycerides From Baseline, by Assigned Dietary Group [ Time Frame: 12 months ]Predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences in Systolic Blood Pressure From Baseline, by Assigned Dietary Group [ Time Frame: 12 months ]Predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Difference in Diastolic Blood Pressure, by Assigned Dietary Group [ Time Frame: 12 Months ]Mean Difference in Diastolic Blood Pressure predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values
- Predicted Mean Difference in Plasma Glucose Level, by Assigned Dietary Group [ Time Frame: 12 months ]Mean Difference in Plasma Glucose Level predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences in Serum Insulin Level From Baseline, by Assigned Dietary Group [ Time Frame: 12 months ]Mean Difference in Serum Insulin Level predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences in C-reactive Protein Level From Baseline, by Assigned Dietary Group [ Time Frame: 12 Months ]Mean Difference in C-reactive Protein Level predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values
- Predicted Mean Differences in Serum Creatinine Level From Baseline, by Assigned Dietary Group [ Time Frame: 12 Months ]Mean Difference in Serum Creatinine Level predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
- Predicted Mean Differences of 10-y Framingham Risk Score From Baseline, by Assigned Dietary Group [ Time Frame: 12 Months ]Mean Difference in 10-y Framingham Risk Score predicted from random-effects models that included diet, time, and diet-by-time interaction term. Markov-chain Monte Carlo techniques were used to impute missing values.
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 22 Years to 75 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Men or women aged 22 - 75 years, any race/ethnicity
- BMI of 30 - 45 k/m2
- Willing and able to provide informed consent
Exclusion Criteria:
- History of self-reported clinical CVD (angina/myocardial infarction, coronary revascularization, heart failure, stroke/transient ischemic attack, peripheral arterial disease)
- Medical condition in which a low-carbohydrate diet may not be advised (diabetes, renal disease, cancer requiring treatment during the past year, osteoporosis, untreated thyroid disease, gout)
- Current use of more than 2 antihypertensive or more than 2 cholesterol-lowering medications
- For women, current pregnancy or breastfeeding or plans to become pregnant during the study period
- Consumption of more than 21 alcoholic beverages per week
- Currently on a diet or using prescription weight loss medications, underwent weight loss surgery, and/or experienced weight loss >15 pounds within 6 months of study entry
- Plans to move out of the study area (>1 hour from study site) or difficulty to come to the study site
- Participation of another household member in the study; employees or persons living with employees of the study
- Participation in other lifestyle intervention trials currently
- At the discretion of the study coordinator
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00609271
Locations
| United States, Louisiana | |
| Tulane University, Office of Health Research | |
| New Orleans, Louisiana, United States, 70112 | |
Sponsors and Collaborators
Tulane University Health Sciences Center
Investigators
| Principal Investigator: | Lydia A Bazzano, MD, PhD | Tulane University |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Lydia A. Bazzano, Associate Professor Epidemiology, Tulane University Health Sciences Center |
| ClinicalTrials.gov Identifier: | NCT00609271 |
| Other Study ID Numbers: |
07-00111 |
| First Posted: | February 7, 2008 Key Record Dates |
| Results First Posted: | November 19, 2018 |
| Last Update Posted: | November 19, 2018 |
| Last Verified: | April 2018 |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Additional relevant MeSH terms:
|
Cardiovascular Diseases |